Home
Categories
EXPLORE
Society & Culture
Comedy
True Crime
Business
Technology
Leisure
Education
About Us
Contact Us
Copyright
© 2024 PodJoint
Loading...
0:00 / 0:00
Podjoint Logo
HK
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/89/d6/59/89d659f6-842b-f713-172e-276b137a7250/mza_13591906078518338376.jpg/600x600bb.jpg
The Lancet Infectious Diseases in conversation with
The Lancet Group
120 episodes
14 hours ago
Lilian Tina Minja and Norbert Heinrich discuss the SUDUCO and DECODE trials in The Lancet Infectious Diseases on two new promising TB drugs, sutezolid and delpazolid, respectively. They also discuss the wider implications of the findings of these trials for TB drug development and treatment. Read the trials: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00213-0/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laninf https://www.thelancet.com/journals/laninf/article/PIIS1473-...
Show more...
Medicine
Education,
Health & Fitness,
Science,
Life Sciences
RSS
All content for The Lancet Infectious Diseases in conversation with is the property of The Lancet Group and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Lilian Tina Minja and Norbert Heinrich discuss the SUDUCO and DECODE trials in The Lancet Infectious Diseases on two new promising TB drugs, sutezolid and delpazolid, respectively. They also discuss the wider implications of the findings of these trials for TB drug development and treatment. Read the trials: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00213-0/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laninf https://www.thelancet.com/journals/laninf/article/PIIS1473-...
Show more...
Medicine
Education,
Health & Fitness,
Science,
Life Sciences
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/89/d6/59/89d659f6-842b-f713-172e-276b137a7250/mza_13591906078518338376.jpg/600x600bb.jpg
Lilian Tina Minja and Norbert Heinrich on TB drug development
The Lancet Infectious Diseases in conversation with
29 minutes
1 month ago
Lilian Tina Minja and Norbert Heinrich on TB drug development
Lilian Tina Minja and Norbert Heinrich discuss a pair of trials they recently published in The Lancet Infectious Diseases, ‘A prospective, randomised, open label phase 2b dose-finding trial of sutezolid in combination with bedaquiline, delamanid and moxifloxacin for pulmonary tuberculosis: SUDOCU’ and ‘A prospective, randomised, open label phase 2b dose-finding trial of delpazolid in combination with bedaquiline, delamanid and moxifloxacin for pulmonary tuberculosis: DECODE’ and the wider imp...
The Lancet Infectious Diseases in conversation with
Lilian Tina Minja and Norbert Heinrich discuss the SUDUCO and DECODE trials in The Lancet Infectious Diseases on two new promising TB drugs, sutezolid and delpazolid, respectively. They also discuss the wider implications of the findings of these trials for TB drug development and treatment. Read the trials: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00213-0/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laninf https://www.thelancet.com/journals/laninf/article/PIIS1473-...